Design of Bi-layer products [Design Issues]

posted by A.Shtaiwi – Jordan, 2020-07-17 12:51 (679 d 01:53 ago) – Posting: # 21732
Views: 2,115

Dear All,

Hope you are well,

I want to ask if anyone has experience or knowledge about reference product with following formulation:
2 active ingredients, one found in the immediate release layer and the other in the modified release layer. The Test product has the same composition. If the product is intended to be submitted to Europe, is it required to analyse both active ingredients in all required studies for modified release products (single dose studies under fast and fed conditions and multiple dose study) or should we analyse active ingredient which found in the immediate release layer only in the single dose study (either fasting or fed as per the information stated in the spc of the product) and analyse other active ingredient in all studies.

I have checked the EMEA guideline for modified release products but I just found information about biphasic release product where the same active ingredient is released in immediate and sustained release form.

Thanks

Complete thread:

UA Flag
Activity
 Admin contact
22,108 posts in 4,630 threads, 1,567 registered users;
online 6 (0 registered, 6 guests [including 5 identified bots]).
Forum time: Friday 14:45 CEST (Europe/Vienna)

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5